Alzheimer's disease (AD) is the most common cause of dementia, representing a major global public health challenge as populations age. It accounts for roughly 60%–80% of all dementia and is characterized by progressive cognitive decline, memory impairment, and eventual loss of independence in daily functioning. The disease unfolds over decades, with neuropathological alterations preceding the onset of clinical symptoms by many years. Alzheimer's disease is closely linked to the accumulation and deposition of cerebral amyloid-β (Aβ) and represents the most common cerebral amyloid deposition disorder. Recent advances in molecular biology, neuroimaging, and biomarker science have revealed a complex, multifactorial pathogenesis involving protein misfolding, neuroinflammation, synaptic dysfunction, vascular factors, and network-level propagation of pathology. This review synthesizes current knowledge on AD terminology, epidemiology and risk factors, clinical phenotypes and natural history, pathophysiological mechanisms, diagnostic approaches (including imaging and fluid biomarkers), and established as well as emerging therapeutic strategies, while also outlining key challenges and future directions.
Citation: Arosh S. Perera Molligoda Arachchige, Bianca Schmiliver, Gabriel Amorim Moreira Alves. Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment[J]. AIMS Neuroscience, 2026, 13(2): 208-243. doi: 10.3934/Neuroscience.2026009
Alzheimer's disease (AD) is the most common cause of dementia, representing a major global public health challenge as populations age. It accounts for roughly 60%–80% of all dementia and is characterized by progressive cognitive decline, memory impairment, and eventual loss of independence in daily functioning. The disease unfolds over decades, with neuropathological alterations preceding the onset of clinical symptoms by many years. Alzheimer's disease is closely linked to the accumulation and deposition of cerebral amyloid-β (Aβ) and represents the most common cerebral amyloid deposition disorder. Recent advances in molecular biology, neuroimaging, and biomarker science have revealed a complex, multifactorial pathogenesis involving protein misfolding, neuroinflammation, synaptic dysfunction, vascular factors, and network-level propagation of pathology. This review synthesizes current knowledge on AD terminology, epidemiology and risk factors, clinical phenotypes and natural history, pathophysiological mechanisms, diagnostic approaches (including imaging and fluid biomarkers), and established as well as emerging therapeutic strategies, while also outlining key challenges and future directions.
| [1] | 2024 Alzheimer's disease facts and figures. Alzheimers Dement 20: 3708-3821. https://doi.org/10.1002/alz.13809 |
| [2] |
Tarawneh R, Holtzman DM (2012) The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med 2: a006148. https://doi.org/10.1101/cshperspect.a006148 
|
| [3] |
Dubois B, Hampel H, Feldman HH, et al. (2016) Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 12: 292-323. https://doi.org/10.1016/j.jalz.2016.02.002
|
| [4] |
Hamberger MJ, Heydari N, Caccappolo E, et al. (2022) Naming in older adults: complementary auditory and visual assessment. J Int Neuropsychol Soc 28: 574-587. https://doi.org/10.1017/S1355617721000552
|
| [5] |
El Haj M, Antoine P, Amouyel P, et al. (2016) Apolipoprotein E (APOE) ϵ4 and episodic memory decline in Alzheimer's disease: A review. Ageing Res Rev 27: 15-22. https://doi.org/10.1016/j.arr.2016.02.002
|
| [6] |
Knopman DS, Amieva H, Petersen RC, et al. (2021) Alzheimer disease. Nat Rev Dis Primers 7: 33. https://doi.org/10.1038/s41572-021-00269-y
|
| [7] |
Au R, Popp Z, Low S, et al. (2025) Reinventing “N” in the A/T/N framework: The case for digital. J Prev Alzheimers Dis 13: 100395. https://doi.org/10.1016/j.tjpad.2025.100395
|
| [8] |
Sperling RA, Aisen PS, Beckett LA, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292. https://doi.org/10.1016/j.jalz.2011.03.003
|
| [9] |
Rabinovici GD, Knopman DS, Arbizu J, et al. (2025) Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement 21: e14338. https://doi.org/10.1002/alz.14338
|
| [10] | Leuzy A, Heurling K, Ashton NJ, et al. (2018) In vivo detection of Alzheimer's disease. Yale J Biol Med 91: 291-300. |
| [11] |
Leuzy A, Bollack A, Pellegrino D, et al. (2025) Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. Alzheimers Dement 21: e14528. https://doi.org/10.1002/alz.14528
|
| [12] | 2025 Alzheimer's disease facts and figures. Alzheimers Dement 21: e70235. https://doi.org/10.1002/alz.70235 |
| [13] |
Peuker E, Cummings M (2003) Anatomy for the acupuncturist--facts & fiction. 1: The head and neck region. Acupunct Med 21: 2-8. https://doi.org/10.1136/aim.21.1-2.2
|
| [14] |
Jorm AF (1991) Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci 240: 218-222. https://doi.org/10.1007/BF02189530
|
| [15] |
Lippert RV, Kraal AZ, Edwards NC, et al. (2025) Age-anchored genetic risk for Alzheimer's disease is associated with markers of cerebrovascular disease, inflammation, and neurodegeneration in older adults without dementia. Alzheimers Dement (N Y) 21: e109833. https://doi.org/10.1002/alz70862_109833
|
| [16] | Bailey M, Ilchovska ZG, Hosseini AA, et al. (2024) The impact of APOE ϵ4 in Alzheimer's disease: a meta-analysis of voxel-based morphometry studies. medRxiv . https://doi.org/10.1101/2024.05.10.24307165 |
| [17] |
Di Battista AM, Heinsinger NM, Rebeck GW (2016) Alzheimer's disease genetic risk factor APOE-ϵ4 also affects normal brain function. Curr Alzheimer Res 13: 1200-1207. https://doi.org/10.2174/1567205013666160401115127
|
| [18] |
Yang LG, March ZM, Stephenson RA, et al. (2023) Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends Endocrinol Metab 34: 430-445. https://doi.org/10.1016/j.tem.2023.05.002
|
| [19] |
Ramesh S, Arachchige ASPM (2023) Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. AIMS Neuro 10: 200-231. https://doi.org/10.3934/Neuroscience.2023017
|
| [20] |
Zhou J, Chen Y, Meng F, et al. (2020) Presenilin 1 and APP gene mutations in early-onset AD families from a southeast region of China. Curr Alzheimer Res 17: 540-546. https://doi.org/10.2174/1567205017666200624195809
|
| [21] |
Żekanowski C, Styczyńska M, Pepłońska B, et al. (2003) Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol 184: 991-996. https://doi.org/10.1016/S0014-4886(03)00384-4
|
| [22] |
Wiseman FK, Al-Janabi T, Hardy J, et al. (2015) A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 16: 564-574. https://doi.org/10.1038/nrn3983
|
| [23] |
A Armstrong R (2019) Risk factors for Alzheimer's disease. Folia Neuropathol 57: 87-105. https://doi.org/10.5114/fn.2019.85929
|
| [24] |
Silva MVF, Loures CMG, Alves LCV, et al. (2019) Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci 26: 33. https://doi.org/10.1186/s12929-019-0524-y
|
| [25] |
Banerjee G, Farmer SF, Hyare H, et al. (2024) Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone. Nat Med 30: 394-402. https://doi.org/10.1038/s41591-023-02729-2
|
| [26] |
Cali I, Cohen ML, Haik S, et al. (2018) Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study. Acta Neuropathol Commun 6: 5. https://doi.org/10.1186/s40478-017-0503-z
|
| [27] |
Marmor A, Meiner Z, Kahana Merhavi S, et al. (2025) Cognitive reserve as a predictor of cognitive decline, but not age of diagnosis in patients with possible young-onset Alzheimer's disease: An underexplored population. J Alzheimers Dis Rep 9: 25424823251383903. https://doi.org/10.1177/25424823251383903
|
| [28] | Crawford L, Loprinzi PD (2019) Alzheimer's disease: memory interference and the role of exercise. Alzheimer's Disease [Internet] . Brisbane (AU): Codon Publication. https://doi.org/10.15586/alzheimersdisease.2019.ch12 |
| [29] |
Rogers SL, Friedman RB (2008) The underlying mechanisms of semantic memory loss in Alzheimer's disease and semantic dementia. Neuropsychologia 46: 12-21. https://doi.org/10.1016/j.neuropsychologia.2007.08.010
|
| [30] |
Benoit M, Dygai I, Migneco O, et al. (1999) Behavioral and psychological symptoms in Alzheimer's disease. Relation between apathy and regional cerebral perfusion. Dement Geriatr Cogn Disord 10: 511-517. https://doi.org/10.1159/000017198
|
| [31] |
Abdi Z, Yong KX, Schott JM, et al. (2025) Pathological characterisation of posterior cortical atrophy in comparison with amnestic Alzheimer's disease. Neuropathol Appl Neurobiol 51: e70007. https://doi.org/10.1111/nan.70007
|
| [32] |
Crutch SJ, Lehmann M, Schott JM, et al. (2012) Posterior cortical atrophy. Lancet Neurol 11: 170-178. https://doi.org/10.1016/S1474-4422(11)70289-7
|
| [33] |
Henry ML, Gorno-Tempini ML (2010) The logopenic variant of primary progressive aphasia. Curr Opin Neurol 23: 633-637. https://doi.org/10.1097/WCO.0b013e32833fb93e
|
| [34] |
Wong S, Strudwick J, Devenney E, et al. (2019) Frontal variant of Alzheimer's disease masquerading as behavioural-variant frontotemporal dementia: a case study comparison. Neurocase 25: 48-58. https://doi.org/10.1080/13554794.2019.1609523
|
| [35] |
Whitwell JL (2024) Atypical clinical variants of Alzheimer's disease: are they really atypical?. Front Neurosci 18: 1352822. https://doi.org/10.3389/fnins.2024.1352822
|
| [36] |
Perera Molligoda Arachchige AS, Garner AK (2023) Seven Tesla MRI in Alzheimer's disease research: State of the art and future directions: A narrative review. AIMS Neurosci 10: 401-422. https://doi.org/10.3934/Neuroscience.2023030
|
| [37] |
Visser PJ, Reus LM, Gobom J, et al. (2003) Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Mol Neurodegener 17: 27. https://doi.org/10.1186/s13024-022-00521-3
|
| [38] |
Liu E, Zhang Y, Wang JZ (2024) Updates in Alzheimer's disease: from basic research to diagnosis and therapies. Transl Neurodegener 13: 45. https://doi.org/10.1186/s40035-024-00432-x
|
| [39] |
Jessen F, Amariglio RE, Buckley RF, et al. (2020) The characterisation of subjective cognitive decline. Lancet Neurol 19: 271-278. https://doi.org/10.1016/S1474-4422(19)30368-0
|
| [40] | Morris JC (2005) Mild cognitive impairment and preclinical Alzheimer's disease. Geriatrics 2005: 9-14. |
| [41] |
Rafii MS, Aisen PS (2023) Detection and treatment of Alzheimer's disease in its preclinical stage. Nat Aging 3: 520-531. https://doi.org/10.1038/s43587-023-00410-4
|
| [42] |
Mizuno K, Wakai M, Takeda A, et al. (2000) Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: an MRI volumetric and memory assessment study. J Neurol Sci 173: 18-24. https://doi.org/10.1016/S0022-510X(99)00289-0
|
| [43] |
Blinkouskaya Y, Weickenmeier J (2021) Brain shape changes associated with cerebral atrophy in healthy aging and Alzheimer's disease. Front Mech Eng 7: 705653. https://doi.org/10.3389/fmech.2021.705653
|
| [44] |
Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68: 1-14. https://doi.org/10.1097/NEN.0b013e3181919a48
|
| [45] |
Tenchov R, Sasso JM, Zhou QA (2024) Alzheimer's disease: exploring the landscape of cognitive decline. ACS Chem Neurosci 15: 3800-3827. https://doi.org/10.1021/acschemneuro.4c00339
|
| [46] |
Rahman MM, Lendel C (2021) Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology. Mol Neurodegener 16: 59. https://doi.org/10.1186/s13024-021-00465-0
|
| [47] |
Krawczuk D, Kulczyńska-Przybik A, Mroczko B (2025) The potential regulators of amyloidogenic pathway of app processing in Alzheimer's disease. Biomedicines 13: 1513. https://doi.org/10.3390/biomedicines13071513
|
| [48] |
Zhou Y, Sun Y, Ma QH, et al. (2018) Alzheimer's disease: amyloid-based pathogenesis and potential therapies. Cell Stress 2: 150-161. https://doi.org/10.15698/cst2018.07.143
|
| [49] |
Tolar M, Hey J, Power A, et al. (2021) Neurotoxic soluble amyloid oligomers drive Alzheimer's pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci 22: 6355. https://doi.org/10.3390/ijms22126355
|
| [50] |
Hein ZM, Karikalan B, Gopalakrishna PK, et al. (2025) Toward a unified framework in molecular neurobiology of Alzheimer's disease: revisiting the pathophysiological hypotheses. Mol Neurobiol 63: 282. https://doi.org/10.1007/s12035-025-05602-0
|
| [51] |
Gulisano W, Maugeri D, Baltrons MA, et al. (2018) Role of Amyloid-β and Tau proteins in Alzheimer's disease: confuting the amyloid cascade. J Alzheimers Dis 64: S611-S631. https://doi.org/10.3233/JAD-179935
|
| [52] |
Jeganathan S, von Bergen M, Mandelkow EM, et al. (2008) The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 47: 10526-10539. https://doi.org/10.1021/bi800783d
|
| [53] |
Llamas-Rodríguez J, Oltmer J, Greve DN, et al. (2022) Entorhinal subfield vulnerability to neurofibrillary tangles in aging and the preclinical stage of Alzheimer's disease. J Alzheimers Dis 87: 1379-1399. https://doi.org/10.3233/JAD-215567
|
| [54] |
Tiraboschi P, Hansen LA, Thal LJ, et al. (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62: 1984-1989. https://doi.org/10.1212/01.wnl.0000129697.01779.0a
|
| [55] |
Zhang X, Fu Z, Meng L, et al. (2018) The early events that initiate β-Amyloid aggregation in Alzheimer's disease. Front Aging Neurosci 10: 359. https://doi.org/10.3389/fnagi.2018.00359
|
| [56] |
Gu L, Guo Z (2013) Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. J Neurochem 126: 305-311. https://doi.org/10.1111/jnc.12202
|
| [57] |
Zhang J, Zhang Y, Wang J, et al. (2024) Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9: 211. https://doi.org/10.1038/s41392-024-01911-3
|
| [58] |
Alavi Naini SM, Soussi-Yanicostas N (2015) Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?. Oxid Med Cell Longev 2015: 151979. https://doi.org/10.1155/2015/151979
|
| [59] |
Chen XQ, Mobley WC (2019) Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric Aβ and Tau species. Front Neurosci 13: 659. https://doi.org/10.3389/fnins.2019.00659
|
| [60] |
Arachchige ASPM (2023) Marijuana's potential in neurodegenerative diseases: an editorial. AIMS Neurosci 10: 175-177. https://doi.org/10.3934/Neuroscience.2023014
|
| [61] |
Chen ZR, Huang JB, Yang SL, et al. (2022) Role of cholinergic signaling in Alzheimer's disease. Molecules 27: 1816. https://doi.org/10.3390/molecules27061816
|
| [62] | Paul S, Jeon WK, Bizon JL, et al. (2015) Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment. Front Aging Neurosci 7: 43. https://doi.org/10.3389/fnagi.2015.00043 |
| [63] |
Teipel SJ, Flatz WH, Heinsen H, et al. (2005) Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 128: 2626-2644. https://doi.org/10.1093/brain/awh589
|
| [64] | Dai MH, Zheng H, Zeng LD, et al. (2017) The genes associated with early-onset Alzheimer's disease. Oncotarget 9: 15132-15143. https://doi.org/10.18632/oncotarget.23738 |
| [65] |
Lanoiselée HM, Nicolas G, Wallon D, et al. (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med 14: e1002270. https://doi.org/10.1371/journal.pmed.1002270
|
| [66] |
Rafii MS, Schlachetzki Z, Barroeta I, et al. (2025) Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology. Lancet Neurol 24: 753-762. https://doi.org/10.1016/S1474-4422(25)00237-6
|
| [67] |
Lott IT, Head E (2019) Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol 15: 135-147. https://doi.org/10.1038/s41582-018-0132-6
|
| [68] |
Devkota S, Maesako M, Wolfe MS (2025) Presenilin-1 familial Alzheimer mutations impair γ-secretase cleavage of APP through stabilized enzyme-substrate complex formation. Biomolecules 15: 955. https://doi.org/10.3390/biom15070955
|
| [69] |
Belaidi AA, Bush AI, Ayton S (2025) Apolipoprotein E in Alzheimer's disease: molecular insights and therapeutic opportunities. Mol Neurodegener 20: 47. https://doi.org/10.1186/s13024-025-00843-y
|
| [70] |
Fortea J, Pegueroles J, Alcolea D, et al. (2024) APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nat Med 30: 1284-1291. https://doi.org/10.1038/s41591-024-02931-w
|
| [71] |
Jack CR, Andrews JS, Beach TG, et al. (2024) Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement 20: 5143-5169. https://doi.org/10.1002/alz.13859
|
| [72] |
Budelier MM, Bateman RJ (2020) Biomarkers of Alzheimer disease. J Appl Lab Med 5: 194-208. https://doi.org/10.1373/jalm.2019.030080
|
| [73] |
Rosenmann H (2012) CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J Mol Neurosci 47: 1-14. https://doi.org/10.1007/s12031-011-9665-5
|
| [74] |
Zhong X, Wang Q, Yang M, et al. (2025) Plasma p-tau217 and p-tau217/Aβ1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer's disease: Insights for research and clinical practice. Alzheimers Dement 21: e14536. https://doi.org/10.1002/alz.14536
|
| [75] |
Aghajanian S, Mohammadifard F, Mohammadi I, et al. (2025) Longitudinal structural MRI-based deep learning and radiomics features for predicting Alzheimer's disease progression. Alzheimers Res Ther 17: 182. https://doi.org/10.1186/s13195-025-01827-2
|
| [76] |
Schaap T, Thropp P, Tosun D, et al. (2024) Timing of Alzheimer's disease biomarker progressions: A two-decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 20: 9060-9067. https://doi.org/10.1002/alz.14306
|
| [77] |
Abushakra S, Doraiswamy PM, Hey JA, et al. (2026) Hippocampal atrophy on magnetic resonance imaging as a surrogate marker for clinical benefit and neurodegeneration in early symptomatic Alzheimer's disease: synthesis of evidence from observational and interventional trials. CNS Drugs 40: 199-214. https://doi.org/10.1007/s40263-025-01251-y
|
| [78] |
Chapleau M, Iaccarino L, Soleimani-Meigooni D, et al. (2022) The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med 63: 13S-19S. https://doi.org/10.2967/jnumed.121.263195
|
| [79] |
Therriault J, Pascoal TA, Lussier FZ, et al. (2022) Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nat Aging 2: 526-535. https://doi.org/10.1038/s43587-022-00204-0
|
| [80] |
Jack CR, Albert MS, Knopman DS, et al. (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257-262. https://doi.org/10.1016/j.jalz.2011.03.004
|
| [81] |
van Oostveen WM, de Lange ECM (2021) Imaging techniques in Alzheimer's disease: a review of applications in early diagnosis and longitudinal monitoring. Int J Mol Sci 22: 2110. https://doi.org/10.3390/ijms22042110
|
| [82] |
Duara R, Loewenstein DA, Potter E, et al. (2008) Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71: 1986-1992. https://doi.org/10.1212/01.wnl.0000336925.79704.9f
|
| [83] |
Roberge X, Brisson M, Laforce RJ (2023) Specificity of entorhinal atrophy MRI scale in predicting Alzheimer's disease conversion. Can J Neurol Sci 50: 112-114. https://doi.org/10.1017/cjn.2021.253
|
| [84] |
Horvath A, Kiss M, Szucs A, et al. (2019) Precuneus-dominant degeneration of parietal lobe is at risk of epilepsy in mild Alzheimer's disease. Front Neurol 10: 878. https://doi.org/10.3389/fneur.2019.00878
|
| [85] |
Mendez MF (2019) Early-onset Alzheimer disease and its variants. Continuum (Minneap Minn) 25: 34-51. https://doi.org/10.1212/CON.0000000000000687
|
| [86] |
Koedam EL, Lehmann M, van der Flier WM, et al. (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21: 2618-2625. https://doi.org/10.1007/s00330-011-2205-4
|
| [87] |
Sluimer JD, Vrenken H, Blankenstein MA, et al. (2008) Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 70: 1836-1841. https://doi.org/10.1212/01.wnl.0000311446.61861.e3
|
| [88] |
Barnes J, Bartlett JW, van de Pol LA, et al. (2009) A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 30: 1711-1723. https://doi.org/10.1016/j.neurobiolaging.2008.01.010
|
| [89] |
Henneman WJ, Sluimer JD, Barnes J, et al. (2009) Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 72: 999-1007. https://doi.org/10.1212/01.wnl.0000344568.09360.31
|
| [90] |
Uchida Y, Nishimaki K, Soldan A, et al. (2025) Change points for dynamic biomarkers in the Alzheimer's disease pathological cascade: A 30-year cohort study. Alzheimers Dement 21: e70544. https://doi.org/10.1002/alz.70544
|
| [91] |
Uchida Y, Hou Z, Gomez-Isaza L, et al. (2025) Quantification of perforant path fibers for early detection of Alzheimer's disease. Alzheimers Dement 21: e70142. https://doi.org/10.1002/alz.70142
|
| [92] |
Uchida Y, Kan H, Sakurai K, et al. (2022) Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations. Front Neurosci 16: 938092. https://doi.org/10.3389/fnins.2022.938092
|
| [93] | Uchida Y, Kan H, Sakurai K, et al. (2022) APOE ɛ4 dose associates with increased brain iron and β-amyloid via blood-brain barrier dysfunction. J Neurol Neurosurg Psychiatry 28: jnnp–2021–328519. https://doi.org/10.1136/jnnp-2021-328519 |
| [94] |
Arachchige ASPM (2023) Neuroimaging with SPECT-MRI: a myth or reality?. AIMS Neurosci 10: 52-55. https://doi.org/10.3934/Neuroscience.2023004
|
| [95] |
Perera Molligoda Arachchige AS (2023) Neuroimaging with PET/MR: moving beyond 3 T in preclinical systems, when for clinical practice?. Clin Transl Imaging 11: 315-319. https://doi.org/10.1007/s40336-023-00572-6
|
| [96] |
Wang Y, Liao W, Wang L, et al. (2025) Advance and prospect of positron emission tomography in Alzheimer's disease research. Mol Psychiatry 30: 4899-4909. https://doi.org/10.1038/s41380-025-03081-2
|
| [97] | Gentry C, Malek-Ahmadi M, Bolas S, et al. (2024) PET imaging in Alzheimer disease: pathology and research insights for technologists. J Nucl Med Technol 52: 306-311. https://doi.org/10.2967/jnmt.124.268916 |
| [98] |
Bao W, Xie F, Zuo C, et al. (2021) PET neuroimaging of Alzheimer's disease: radiotracers and their utility in clinical research. Front Aging Neurosci 13: 624330. https://doi.org/10.3389/fnagi.2021.624330
|
| [99] |
Pontecorvo MJ, Mintun MA (2011) PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther 3: 11. https://doi.org/10.1186/alzrt70
|
| [100] | American Academy of NeurologyDiagnosis of dementia, guideline detail (2001). [cited 2020 July 31]. Available from: https://www.aan.com/Guidelines/home/GuidelineDetail/42 |
| [101] |
Cummings J, Zhou Y, Lee G, et al. (2024) Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y) 10: e12465. https://doi.org/10.1002/trc2.12465
|
| [102] |
Cummings JL, Zhou Y, Lee G, et al. (2023) Alzheimer's disease drug development pipeline: 2025. Alzheimers Dement (N Y) 11: e70098. https://doi.org/10.1002/trc2.70098
|
| [103] |
Miculas DC, Negru PA, Bungau SG, et al. (2022) Pharmacotherapy evolution in Alzheimer's disease: current framework and relevant directions. Cells 12: 131. https://doi.org/10.3390/cells12010131
|
| [104] | Dementia: Assessment, management and support for people living with dementia and their carers, NICE Guideline, No. 97. [cited 2026 March 03]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536484/ |
| [105] | World Health OrganizationRisk reduction of cognitive decline and dementia: WHO guidelines (2019). [cited 2026 March 03]. Available from: https://www.who.int/publications/i/item/9789241550543 |
| [106] |
Wu CK, Fuh JL (2025) A 2025 update on treatment strategies for the Alzheimer's disease spectrum. J Chin Med Assoc 88: 495-502. https://doi.org/10.1097/JCMA.0000000000001252
|
| [107] |
Kivipelto M, Solomon A, Ahtiluoto S, et al. (2013) The finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimers Dement 9: 657-665. https://doi.org/10.1016/j.jalz.2012.09.012
|
| [108] |
Pravinkumar Ingle, Yen Ling Lee, Xin Yun Wong, et al. (2025) Novel therapeutic approaches in Alzheimer's disease. Current Drug Therapy 20: 929-940. https://doi.org/10.2174/0115748855332142240830114503
|
| [109] |
Li X, Ji M, Zhang H, et al. (2023) Non-drug therapies for Alzheimer's disease: a review. Neurol Ther 12: 39-72. https://doi.org/10.1007/s40120-022-00416-x
|
| [110] |
Wang S, Xu H, Liu G, et al. (2025) Non-pharmacological treatment of Alzheimer's disease: an update. Front Aging Neurosci 17: 1527242. https://doi.org/10.3389/fnagi.2025.1527242
|
| [111] |
Kaufer D (2002) Treatment of neuropsychiatric symptoms in Alzheimer's disease. Rev Neurol 35: 846-850. https://doi.org/10.33588/rn.3509.2002003
|
| [112] |
Chen C, Katayama S, Lee JH, et al. (2025) Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. J Prev Alzheimers Dis 12: 100160. https://doi.org/10.1016/j.tjpad.2025.100160
|
| [113] |
Sims JR, Zimmer JA, Evans CD, et al. (2023) Donanemab in early symptomatic Alzheimer disease: the trailblazer-alz 2 randomized clinical trial. JAMA 330: 512-527. https://doi.org/10.1001/jama.2023.13239
|
| [114] |
Abdelazim K, Allam AA, Afifi B, et al. (2024) The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Neurol Sci 45: 3583-3597. https://doi.org/10.1007/s10072-024-07477-w
|
| [115] |
Ameen T, Ali U, Salma O, et al. (2025) Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease. Egypt J Neurol Psychiatr Neurosurg 61: 37. https://doi.org/10.1186/s41983-025-00968-3
|
| [116] |
van Dyck CH, Swanson CJ, Aisen P, et al. (2023) Lecanemab in early Alzheimer's disease. N Engl J Med 388: 9-21. https://doi.org/10.1056/NEJMoa2212948
|
| [117] |
Hampel H, Elhage A, Cho M, et al. (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146: 4414-4424. https://doi.org/10.1093/brain/awad188
|
| [118] |
Budd Haeberlein S, Aisen PS, Barkhof F, et al. (2023) Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis 9: 197-210. https://doi.org/10.14283/jpad.2022.30
|
| [119] |
Alkhalifa AE, Al Mokhlf A, Ali H, et al. (2025) Anti-amyloid monoclonal antibodies for Alzheimer's disease: evidence, ARIA risk, and precision patient selection. J Pers Med 15: 437. https://doi.org/10.3390/jpm15090437
|
| [120] |
Siemers E, Hitchcock J, Sundell K, et al. (2023) ACU193, a monoclonal antibody that selectively binds soluble Aß oligomers: development rationale, phase 1 trial design, and clinical development plan. J Prev Alzheimers Dis 10: 19-24. https://doi.org/10.14283/jpad.2022.93
|
| [121] |
Abushakra S, Porsteinsson AP, Sabbagh M, et al. (2023) APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE ϵ4/ϵ4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics. Alzheimers Dement (N Y) 10: e12498. https://doi.org/10.1002/trc2.12498
|
| [122] |
Steinfield SR, Stenn DF, Chen H, et al. (2025) A review of the clinical progress of CT1812, a Novel Sigma-2 Receptor Antagonist for the Treatment of Alzheimer's Disease. Pharmaceuticals (Basel) 18: 659. https://doi.org/10.3390/ph18050659
|
| [123] |
Congdon EE, Ji C, Tetlow AM, et al. (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19: 715-736. https://doi.org/10.1038/s41582-023-00883-2
|
| [124] |
Martín-Acosta P, Xiao X (2021) PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem 210: 112993. https://doi.org/10.1016/j.ejmech.2020.112993
|
| [125] | Novo NordiskNovo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression (2025). [cited 2025 December 03]. Available from: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462 |
| [126] |
Zhang F, Meng Y, Zhang W (2026) Deep brain stimulation for the treatment of Alzheimer's disease: A safer and more effective strategy. Neural Regen Res 21: 1899-1909. https://doi.org/10.4103/NRR.NRR-D-24-01088
|
| [127] |
Rivers-Auty J, Mather AE, Peters R, et al. (2020) Anti-inflammatories in Alzheimer's disease-potential therapy or spurious correlate?. Brain Commun 2: fcaa109. https://doi.org/10.1093/braincomms/fcaa109
|
| [128] |
Long H, Simmons A, Mayorga A, et al. (2024) Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimers Res Ther 16: 235. https://doi.org/10.1186/s13195-024-01599-1
|
| [129] |
Farlow M (2002) A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr 14: 93-126. https://doi.org/10.1017/s1041610203008688
|
| [130] | McShane R, Westby MJ, Roberts E, et al. (2019) Memantine for dementia. Cochrane Database Syst Rev 3: CD003154. https://doi.org/10.1002/14651858.CD003154.pub6 |
| [131] | Battle CE, Abdul-Rahim AH, Shenkin SD, et al. (2021) Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev 2: CD013306. https://doi.org/10.1002/14651858.CD013306.pub2 |
| [132] |
Kabir MT, Sufian MA, Uddin MS, et al. (2023) NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer's therapy. Curr Pharm Des 25: 3506-3518. https://doi.org/10.2174/1381612825666191011102444
|
| [133] |
Shaukat A, Riaz R, Khaliq N, et al. (2025) Brexpiprazole: Pioneering medication for managing agitation in Alzheimer's disease. J Alzheimers Dis Rep 9: 25424823251379881. https://doi.org/10.1177/25424823251379881
|
| [134] |
Ragsdale SM, Radovich JM, Coiduras II, et al. (2025) Dual orexin receptor antagonists as promising therapeutics for Alzheimer's disease. NPJ Biol Timing Sleep 2: 11. https://doi.org/10.1038/s44323-025-00025-5
|
| [135] | Haddad HW, Malone GW, Comardelle NJ, et al. (2022) Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's disease: A Comprehensive Review. Health Psychol Res 10: 31925. https://doi.org/10.52965/001c.31925 |
| [136] |
Arshad F, Alladi S (2025) Disease-modifying drugs for Alzheimer's disease: bending the curve. Ann Indian Acad Neurol 28: 640-645. https://doi.org/10.4103/aian.aian_748_25
|
| [137] |
Sperling RA, Donohue MC, Raman R, et al. (2023) Trial of solanezumab in preclinical Alzheimer's disease. N Engl J Med 389: 1096-1107. https://doi.org/10.1056/NEJMoa2305032
|
| [138] |
Lozupone M, Dibello V, Sardone R, et al. (2023) The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies. Expert Opin Drug Discov 18: 515-526. https://doi.org/10.1080/17460441.2023.2200245
|
| [139] |
Rawal S, Wildsmith KR, Aluri J, et al. (2025) An anti-tau therapeutic antibody etalanetug (E2814): A Phase 1, first-in-human (FIH) study of single and multiple ascending doses in healthy subjects. Alzheimer Dis Assoc Disord 39: 151-157. https://doi.org/10.1097/WAD.0000000000000680
|
| [140] |
Zhang Y, Tang C, He Y, et al. (2024) Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models. Biomed Pharmacother 180: 117540. https://doi.org/10.1016/j.biopha.2024.117540
|
| [141] |
Haroon J, Jordan K, Mahdavi K, et al. (2024) A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias. Medicine (Baltimore) 103: e39027. https://doi.org/10.1097/MD.0000000000039027
|
| [142] |
Dubois B, López-Arrieta J, Lipschitz S, et al. (2023) Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther 15: 39. https://doi.org/10.1186/s13195-023-01169-x
|
| [143] |
Wang HY, Cecon E, Dam J, et al. (2023) Simufilam reverses aberrant receptor interactions of filamin a in Alzheimer's disease. Int J Mol Sci 24: 13927. https://doi.org/10.3390/ijms241813927
|
| [144] |
Johnston JL, Reda SM, Setti SE, et al. (2023) Fosgonimeton, a novel positive modulator of the HGF/MET system, promotes neurotrophic and procognitive effects in models of dementia. Neurotherapeutics 20: 431-451. https://doi.org/10.1007/s13311-022-01325-5
|
| [145] |
Bakker A, Rani N, Mohs R, et al. (2024) The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ϵ4 non-carriers with mild cognitive impairment due to Alzheimer's disease. Alzheimers Dement (N Y) 10: e70004. https://doi.org/10.1002/trc2.70004
|
| [146] |
Johnson KG, Kaplitt M, Kaminsky S, et al. (2025) Topline results from Phase 1/2 AAV gene therapy (LX1001) in APOE4/4 homozygotes with Alzheimer's disease. Alzheimers Dement 21: e101538. https://doi.org/10.1002/alz70859_101538
|
| [147] |
Cherdak MA, Mkhitaryan EA, Tkacheva ON (2025) Differential diagnosis of Alzheimer's disease and vascular cognitive disorders. Neurosci Behav Physi 55: 1201-1209. https://doi.org/10.1007/s11055-025-01879-9
|
| [148] |
Nelson PT, Dickson DW, Trojanowski JQ, et al. (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142: 1503-1527. https://doi.org/10.1093/brain/awz099
|
| [149] |
Richardson TE, Walker JM, Farrell K, et al. (2025) Primary age-related tauopathy. Acta Neuropathol 150: 40. https://doi.org/10.1007/s00401-025-02943-x
|
| [150] |
Yokota O, Miki T, Nakashima-Yasuda H, et al. (2024) Pure argyrophilic grain disease revisited: independent effects on limbic, neocortical, and striato-pallido-nigral degeneration and the development of dementia in a series with a low to moderate Braak stage. Acta Neuropathol Commun 12: 121. https://doi.org/10.1186/s40478-024-01828-6
|
Figures(3) / Tables(1)
Arosh S. Perera Molligoda Arachchige, Bianca Schmiliver, Gabriel Amorim Moreira Alves. Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment[J]. AIMS Neuroscience, 2026, 13(2): 208-243. doi: 10.3934/Neuroscience.2026009
DownLoad: